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Chapter 11
Enabling Posthumous Medical Data 
Donation: A Plea for the Ethical Utilisation 
of Personal Health Data
Jenny Krutzinna, Mariarosaria Taddeo, and Luciano Floridi
Abstract This article argues that personal medical data should be made available 
for scientific research, by enabling and encouraging individuals to donate their med-
ical records once deceased, in a way similar to how they can already donate organs 
or bodies. This research is part of a project on posthumous medical data donation 
(PMDD) developed by the Digital Ethics Lab at the Oxford Internet Institute. Ten 
arguments are provided to support the need to foster posthumous medical data 
donation. Two major risks are also identified—harm to others, and lack of control 
over the use of data—which could follow from unregulated donation of medical 
data. The argument that record-based medical research should proceed without 
the need to ask for informed consent is rejected, and it instead a voluntary 
and participatory approach to using personal medical data should be followed. 
The analysis concludes by stressing the need to develop an ethical code for data 
donation to minimise the risks providing five foundational principles for ethical 
medical data donation; and suggesting a draft for such a code.
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Numerous health conditions affecting large parts of the population remain under- 
researched. The consequence is that preventative measures, treatments and/or cures 
are lacking. Some of these illnesses, such as Alzheimer’s dementia or Parkinson’s 
disease, have devastating effects on their sufferers, and currently lack adequate 
treatment. While some progress has been made in discovering genetic or biological 
markers to identify people at greater risk of contracting certain diseases, little is 
known about the interpersonal differences that make someone a sufferer while spar-
ing others with identical markers. Identifying and understanding these underlying 
differences is hard partly because of a lack of relevant data. The data required for 
such scientific progress need to be wide and longitudinal, but this is difficult and 
costly to obtain within traditional clinical research studies. At the same time, some 
data that exist are currently unavailable to research due to the absence of an ade-
quate framework to streamline the currently onerous access procedures. Although 
individuals can volunteer while alive their data to private corporations by accepting 
terms and conditions to this effect, it is not yet possible to give one’s medical data 
(whether during life or after death), for research purposes to a public institution. Nor 
is there any regulatory or ethical framework in place to guide the donation process. 
In this article, we argue that this constitutes an unethical failure to utilise data that 
are of immense value and importance in the quest to improve public health and to 
promote the common good. The focus is on posthumous medical data donation 
(PMDD), which should be enabled as a matter of urgency by putting in place an 
ethical code of PMDD.
The article starts with an outline of what is meant by PMDD, followed by an 
explanation of the reasons for enabling PMDD. These consist of 10 arguments in 
favour of PMDD, as well as arguments against the alternative approach suggested 
by some researchers (e.g. Mann et al. 2016), namely the removal of the need for 
individual informed consent in Big Data health research. Comparing PMDD to 
other types of biomedical donations that already take place, we argue that the 
existing ethical frameworks from other donation schemes provide useful guid-
ance, but do not suffice to ensure ethical PMDD. Therefore, we stress the need to 
define an ethical code specific to PMDD, and propose five foundational principles 
for such a code.
11.2  What Is Posthumous Medical Data Donation?
Posthumous medical data donation (PMDD) refers to the act of donating one’s per-
sonal medical data after death. Medical data is meant to describe here data that are 
routinely collected in a health system, whenever individuals use health services, 
throughout their life. Such data hold enormous potential for medical research and 
for health and care improvements on a large scale. However, personal medical data 
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currently remain mostly inaccessible for researchers due to a lack of enabling regu-
lation. Issues of consent, ownership, and privacy, among others, mean that upon 
death, an individual’s data become ‘locked in’. Depending on the jurisdiction, gain-
ing access for research purposes is cumbersome, if possible at all (Shaw et al. 2015). 
An effective way to solve this problem is by making provisions for enabling the 
donation of one’s own medical data after death. So far, the donation of medical data 
has received limited attention (Shaw et al. 2016).
PMDD is different from medical data sharing,1 which happens while one is alive, 
and from medical data philanthropy, which describes the opening, to external access 
and use, by private companies and public organisations, of their data sets, for chari-
table purposes (Taddeo 2016).2 Data sharing and philanthropy are important sources 
of medical information, but, as we shall argue in the rest of this article, posthumous 
medical data donation is motivated by different reasons, and is less risky and more 
easily achievable than either data sharing or data philanthropy (Table 11.1).
Other types of donation in the medical field are already very common. Indeed, a 
significant part of the medical system relies on donations to save lives, educate and 
teach the medical profession, and advance medical knowledge in general. Examples 
include blood, organ and tissue donations, gamete donations, stem cell and cord 
blood donations, as well as brain and body donations for research and educational 
purposes. It is even possible to donate one’s body for commercial or artistic pur-
poses, albeit controversially, for instance to the anatomist and inventor of plastina-
tion, Gunther von Hagens, and his (in)famous “Body Worlds” exhibition.3
Unlike these types of biomedical donation, the donation of medical data is con-
ceptually problematic: a lack of materiality and the simultaneity of data pose a 
challenge to the notion that data can be “donated” in the conventional sense 
(Prainsack 2018). However, at least in the context of post-mortem donations, the 
use of ‘donation’ appears preferable to more general terms, like ‘sharing’, as the 
former rules out the possibility of a retraction of the data by the donor or of joint 
use with the donor.
When it comes to donating medical data, there are specific subsets of data that 
can currently be donated. One such example is genomic data (Haeusermann et al. 
1 It has been argued that data sharing is a misleading concept and should be abandoned: See “Why 
we should stop talking about data sharing”, Barbara Prainsack, (2015), http://dnadigest.org/why-
we-should-stop-talking-about-data-sharing/ (accessed July 20, 2018).
2 Also see: “Data Philanthropy: Where Are We Now?” United Nations Global Pulse. https://www.
unglobalpulse.org/data-philanthropy-where-are-we-now (accessed March 5, 2018).
3 See https://bodyworlds.com/ (accessed November 5, 2018).
Table 11.1 Differences between data donation, sharing and philanthropy
Data source Dataset
Data donation Deceased individual Single dataset
Data sharing Living individual, researcher Single or multiple
Data philanthropy Institutional Multiple, large-scale
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2017). For instance, the Personal Genome Project enables individuals to “donate” 
their full genome for research purposes.4 Another example is data given during 
participation in medical research projects, studies, or clinical trials. However, the 
donation of a more comprehensive dataset, such as in the form of personal medical 
records (PMRs) has not been systematically enabled so far. The collection and use 
of medical data for research purposes has mostly been via the aforementioned 
patient surveys, clinical studies, and trials. As the type and number of patients 
recruited to these is rather limited, a vast amount of potential data is not included 
and remains unused. At the same time, the infrastructure of our health services is 
changing to enable—in theory—the wider sharing of data with health care profes-
sionals and researchers. For instance, through the electronic health records (EHRs) 
currently being introduced within NHS England, individuals can share their own 
records via a link. This still faces some challenges, partly due to different data 
formats and a lack of data system interoperability.5 In addition, serious limitations 
of this approach relate to the quality of information and the fact that the data available 
in these EHRs tend to be incomplete, and vary from General Practitioner (GP) 
practice to GP practice, but these are predominantly practical obstacles that could 
easily be overcome (Floridi and Illari 2016).
The failure to utilise fully the health data available in PMRs, which often already 
exist in digitised form as EHRs, has a huge opportunity cost. It has a negative effect 
on medical research, given that an incredibly valuable resource remains untapped 
when its utilisation could lead to significant advances in medical knowledge. In 
times when public health is in desperate need of improvement and when many seri-
ous health conditions are poorly understood, this is unacceptable and, it is argued, 
unethical. It is crucial to enable individuals to donate their medical data and enable 
its use for research for the common good.
11.3  Why We Should Enable PMDD
In light of the potential benefit to be derived from the utilisation of PMRs for 
research purposes, some have suggested that obtaining informed consent from 
individuals is inappropriate for record-based research (Mann et al. 2016). This position 
emphasises the benefit for society at large, and maintains that because of a “duty to 
easy rescue”—i.e. that individuals are under a moral obligation to benefit others 
where there is no or minimal risk to themselves—one would be justified in bypassing, 
in this particular context, what is otherwise a fundamental principle in research ethics: 
informed consent. Indeed, the current legal rules in many Western jurisdictions 
4 The use of “donate” in the context of the PGP is based on the PGPs own description: See https://
www.personalgenomes.org.uk/ (accessed July 20, 2018).
5 An additional and often overlooked challenge lies in the fact that at least the textual passages of 
any medical records are likely to be the subject of copyright and would need to be released prior to 
any donation. However, practical solutions to such challenges could be found, for instance, by 
reaching an agreement with public health institutions, such as the NHS, on an organisational level.
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allow for this type of research to proceed without such consent, but this article is 
concerned primarily with the ethical considerations relating to PMDD, and not with 
legal frameworks.
There is clearly some merit in reconsidering how informed consent operates in 
modern data- or record-based medical research, where in order to maximise utility, 
data often need to be repurposed in ways that could not have been anticipated at the 
time of data collection. Rather than negating a need for consent in such instances, 
however, we consider it ethically preferable to enable those individuals already 
willing to volunteer their data to do so, even if this may lead to an initial and perhaps 
unavoidable bias, but one which may also be acceptable in order to start the pro-
cess.6 Note that empirical research into patient attitudes suggests that they are 
many.7 This approach will foster trust and encourage wider social acceptance of the 
collection and re-use of medical data. However, if such a fully voluntary approach 
does not yield sufficient participation, a move towards an alternative approach is 
conceivable, e.g. through an opt-out system or record-based research with less con-
sent requirements attached. In addition, abandoning the informed consent require-
ment on the basis of an analogical reasoning in terms of rescue seems inappropriate, 
where no discernible individual is immediately saved or even treated. The long-term 
time horizon of most medical research projects also makes it rather unlikely that the 
patient data subjects will ever become beneficiaries of any research findings resulting 
directly from their own records. This is obviously impossible in the case of data of 
the deceased. Therefore, the idea of simply using the available data without first 
obtaining informed consent is dismissed, even where this would be within the 
current limits of the law. Instead, from an ethical perspective, PMDD should be 
enabled and encouraged as a fully voluntary action for the following ten reasons.
 (1) It is unethical to frustrate the “will-to-do-it” without proper justification. 
Although no individual donor will receive a benefit at the point of donation, 
the ability to contribute to the advancement of medicine and act as a moral 
agent can provide a significant benefit during one’s lifetime. Studies with 
organ, body, and brain donors show a strong desire to do post-mortem good, 
and suggest that medical data would be no different (Steinsbekk et al. 2013). 
Indeed, the Personal Genome Project and patient networks, such as patients-
likeme.com, offer good examples of the case in point.8
 (2) The concept of altruism is well-established and should include data donation 
for the common good.9 There is evidence that most individuals already desire 
6 This approach is clearly associated with some trade-offs, such as the creation of a dataset that is 
biased in favour of individuals who are willing to donate. However, this is not as such an argument 
against the choice of focusing initially on those willing to donate, as it has the benefit of using these 
“low-hanging fruit” to grow a wider social acceptance of PMDD and thus increasing the willing-
ness to donate data.
7 For example, see: Wellcome Trust Monitor: Wave 3 (full report). https://wellcome.ac.uk/sites/
default/files/monitor-wave3-full-wellcome-apr16.pdf (accessed Sept 21, 2017).
8 See https://www.personalgenomes.org.uk/ and https://www.patientslikeme.com/
9 In the present context, the concept is to be broadly understood, as it is of course difficult to ascer-
tain whether an individual really is an altruist, or whether other motives are behind a choice to act 
ethically.
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to act morally, and may do so without the need for further encouragement 
when provided with the right information, a straightforward procedure, and 
appropriate safeguards (Richardson and Hurwitz 1995). With regard to PMDD, 
the lack of regulatory guidance and practical possibilities of donating data 
hampers the moral agency of potential donors.
 (3) Fairness is also crucial, as it ensures that burdens and benefits are shared 
across society. If one receives healthcare, it is only fair that one gives back. 
This is an infra-generational argument, since members of the current genera-
tion will be donating data for the benefit of others, much like they currently 
benefit from the contributions of previous generations to medical knowledge. 
Arguably, there is a moral obligation to participate in scientific research 
(Harris 2005).
 (4) PMDD is an appeal to inter-generational solidarity, as future generations will 
benefit from past generations and will become more motivated to donate to 
future generations in turn. Recently, the notion of solidarity has experienced a 
revival as a framework to direct biomedicine beyond the dichotomy of per-
sonal benefit and the common good (Prainsack 2017). Such arguments suggest 
that there is a need to nudge less altruistic individuals to act more responsibly, 
and to take on their share of the collective burden of contributing to medical 
knowledge (Prainsack and Buyx 2017).
 (5) PMDD would foster a (human) right to science. It has been argued that this 
includes a human right to participate in the scientific process in its entirety 
(Vayena and Tasioulas 2015). Of course, this is not to say that a right to donate 
one’s medical record implies a receiver’s duty to use these data, as it is advis-
able to retain the option to reject a donation where this carries significant ethi-
cal risks. This is standard practice in whole-body donation programmes, where 
acceptance of a donation is contingent on the health status of the donor and the 
demand by the accepting institution (Riederer et al. 2012).
 (6) There is a strong economic argument to be made. Using the data that are 
already being collected during health and social care to advance the body of 
medical knowledge would enable a more cost-effective administration of 
healthcare. In addition, the more data are donated, the more value the old data 
have. This scale issue is typical of the digital, and makes it economically sen-
sible to encourage PMDD.10
 (7) It is crucial to facilitate PMDD immediately, as the trend towards commerciali-
sation of personal health data is growing, and this may leave the public at risk 
of missing out. Public and commercial benefits are often intertwined, but there 
is a great risk that a lack of public systems that enable the donation of data may 
lead to the collection of such data occurring exclusively in the private/commer-
cial sphere and that, consequently, the use of data for public  benefit may become 
10 See the NHS Digital Business Plan 2017–2018. https://digital.nhs.uk/business-plan-2017-2018 
(accessed March 5, 2018).
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impossible, or at least restricted to research that has significant commercial 
value. Such a market is already emerging for individuals to sell their own data 
to companies. This is the case of Zenome.io, which combines blockchain tech-
nology and digital currency to allow individuals to sell their personal genomic 
information.11 Soon, more comprehensive platforms might encourage individu-
als to sell their full electronic health records, as these become increasingly 
available to patients. A socio-political decision to take the initiative on PMDD 
is thus urgently needed to seize this opportunity and to avoid serious negative 
implications for public health research, once this will be locked out of an 
increasingly commercialised industry in personal medical data, or has to pay 
for access, in the absence of a public data donation scheme.
 (8) PMDD is also a matter of logical coherence. Considering that (most) people 
can already donate their organs and blood, and that it is possible to extract 
substantial data from those donations, it is logically incoherent not to allow 
PMDD.  Furthermore, implicitly, individuals are already allowed and often 
enabled to give away freely their personal data to private corporations, often 
for uncertain purposes, as the terms and conditions of many commercial plat-
forms make clear.
 (9) Two key risks are diminished in PMDD, as both consent and privacy are less 
troublesome where the data relate to a deceased as opposed to a living person. 
This would avoid or at least mitigate many of the problems currently arising in 
the context of data sharing, as PMDD poses significantly less pressure on indi-
vidual privacy, ownership, and consent.
 (10) Finally, data sharing by research institutions has been encouraged in recent 
years and is now considered part of good scientific conduct, as it fosters trans-
parency, replicability of studies, and leads to efficient use of research data. 
Given that most of the reasons for scientific data sharing also apply to PMDD, 
a decision to promote one but not the other is logically and ethically 
inconsistent.
While other types of medical donation (such as tissue donation) have been the sub-
ject of extensive debate, resulting in ethical and governance frameworks and 
national schemes, this has yet to occur for medical data donation. At the same time, 
public relations campaigns are ongoing to promulgate the need to utilise health data 
wisely and ethically. The high-profile UK campaign “Understanding Patient Data”, 
which is jointly funded by the Wellcome Trust, the Medical Research Council, the 
Department of Health and Social Care, the Economic and Social Research Council, 
and Public Health England, aims to “support discussions with the public, patients 
and healthcare professionals about uses of health and care data”.12 This is an unethi-
cal asymmetry, since the lack of opportunity for individuals to donate their PMRs 
11 Zenome  – Your DNA is an asset. Zenome is a market. https://zenome.io/ (accessed Oct 31, 
2017).
12 Understanding Patient Data. http://understandingpatientdata.org.uk/ (accessed November  5, 
2018).
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prevents them from acting altruistically by donating their data for the common 
good, despite public funding invested in educating the public about the need to 
make such data accessible for research within the health service. Research into the 
harms of non-use of health data has concluded that these are hard to prove, but that 
there are significant consequences that need to be addressed in a move towards 
socially responsible reuse of data (Jones et  al. 2017). In addition, the aforemen-
tioned study did not consider the social harm of preventing people from doing what 
they deem to be morally important. That this is a real concern was shown by some 
participants in a large biobank study in Norway, where the desire to contribute to the 
common good was frequently brought up (Steinsbekk et al. 2013). Once all this is 
combined with the potential value that such data hold for medical research, it pro-
vides a strong reason for remedying the current missed opportunity. The fact that the 
current lack of a mechanism for PMDD is more likely to be explained by regulatory 
inertia than a deliberate decision against it on ethical grounds provides even more 
reason to remedy the situation. So, how does PMDD compare to the existing types 
of biomedical donation that are already managed by specific ethical guidelines and 
governance frameworks? The next section addresses this question.
11.4  How Does PMDD Compare to Other Biomedical 
Donations?
A number of types of biomedical donation are already firmly established in several 
health systems around the world. Currently, there are at least seven types of physical 
donations, plus two where the donation consists of a specific data set. Given this 
abundance of donation schemes, one might question the need for yet another frame-
work and suggest instead an ethical approach by analogy. However, as Table 11.2 
indicates by focusing on the United Kingdom, there are some morally significant 
differences among existing schemes and the proposed PMDD.
11.4.1  Key Differences Among Existing Biomedical Donation 
Schemes
The first key difference between PMDD and the most common donation schemes is 
the lack of physical intrusion. Although donating medical data can be described as 
being intrusive to private life, it does not involve a physical act, or indeed any action 
on behalf of the donor other than giving consent. This is also a one-off task, as there 
is no opportunity for re-contact when the donor is deceased.
This leads to the second key difference: donor status. Blood, gametes, cord 
blood, and tissue are usually donated by living people, as are some organs (e.g. 
some kidneys). However, even where the donations are by the deceased, the living 
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relatives are typically directly involved: organ donations are checked with family 
members prior to proceeding, and the urgency of the process (with arrangements 
typically made within 24 h of death) can put immense pressure on relatives. With 
PMDD, it might be equally sensible to bring family members on board, even where 
the deceased have clearly expressed their wishes, but no urgency is required as the 
utility of the data has no expiry date.
A third difference relates to the materiality of data: medical or any kind of digital 
data are non-material, unlike other biomedical donations. This means, for instance, 
that data cannot be “taken out” of one individual and put into another – as would be 
the case in organ or blood donations.
This is linked to a final difference worth stressing, namely that of the beneficiary. 
While blood, cord blood, and gamete donations can be used to benefit oneself in the 
future (although that might be more accurately described as a safeguard than a 
donation), with other donations, including PMDD, the beneficiaries are necessarily 
others. In addition, where the purpose of the donation is non-clinical there is no 
immediate benefit to anyone in particular. The benefit is of a more general nature, 
such as the advancement of clinical knowledge through research, or the teaching 
and training of future health care professionals. When it comes to donations that 
involve health or medical data, as opposed to a physical donation, the key difference 
lies in the research question. Typically, clinical research studies and trials will 
attempt to answer a specific question, or address a concrete hypothesis, whereas 
PMDD would be used for more general research and promote serendipity in 
research.13 Researchers in traditional clinical studies will have to re-contact their 
participants if they wish to use the data for further or additional research, this 
requirement does not apply in PMDD. In addition, living participants can change 
their mind at any point and withdraw their consent, meaning that their data is 
removed from any research in so far as this is practically possible, which again does 
not apply in PMDD, where active consent management is an impossibility.
These differences listed above are only some of the most significant ones between 
existing forms of biomedical donation and PMDD. The list is by no means exhaus-
tive. Yet, the comparison suffices to highlight that reliance on existing frameworks 
is likely to fall short of offering the ethical guidance required to enable safe 
PMDD. This is also because, although some important risks are minimised, PMDD 
is not without its own risks. These risks need to be carefully managed while maxi-
mising the future utility of the donated data. This makes it of utmost importance to 
ensure that PMDD is done ethically, and in particular safely and fairly, without 
creating any unnecessary impediment to either the donor or the health researcher 
using their data.
13 With the exception of biobanks, where data are collected for a range of future research studies.
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11.5  The Need for an Ethical Code
Broadly speaking, two main sources of risks can be associated with PMDD, one 
resulting from the non-individual nature of medical data and one resulting from 
source of the data being a deceased individual without any control over future uses 
of the data.
The first source concerns the nature of the donated medical data, specifically that 
medical data is seldom just about one individual but also often relates to others, who 
may be harmed as a result Some of the donor’s medical data may reveal sensitive 
information about related people. Relational issues arise, for instance, where 
genomic data reveal information about family members. Similarly, information 
found in psychological or psychiatric records may well contain sensitive informa-
tion about others, including family members, as this often plays a significant part in 
the treatment of mental illness. Sexual health and reproductive information are fur-
ther examples of sensitive medical data that typically relate to at least one other 
person. Harms to others might also be caused when insights derived from donated 
data are used for profiling purposes, which might be discriminatory and unfair to 
individuals to whom it is applied. This risk becomes more acute when donated 
medical data is sensitive, for example when relating to a particular (other) individ-
ual or a sensitive condition. In some cases, the risks may be such to embargo a dona-
tion, or in extreme cases to disallow an individual from participating in PMDD, 
despite a personal desire to do so. An example could be close relatives of acting 
politicians, where there is a national interest in avoiding the exposure of vulner-
abilities to outside influences. Similarly, some conditions, like hereditary diseases 
or mental illness, may carry a significantly greater risk of becoming a target of 
discrimination, making it preferable to avoid PMDD. The overall cost of this restric-
tion would be minimal, as the value of PMDD lies in well-curated, large data sets, 
rather than individual data sets. It is important to understand that, when shared data 
pose a serious risk, it would be ethically justified and sensible to reject the particular 
data donation, as the limited value of a single data set (or even of a particularly 
valuable one), is outweighed by the risks to other, living members of society. The 
decision as to when to reject a donation should be strictly limited to those cases 
where the risk to others is likely and serious, to avoid that overcautiously approaches 
may lead to the dismissal of valuable data sets that could be useful to study less 
common conditions and rare diseases.
In summary, fears around potential harms to close relatives do not represent an 
argument against PMDD. The risks just highlighted are not specific to PMDD but 
rather refer to the kind of data in question, not the actual act of donating. This means 
that all the risks generally associated with biomedical data also apply in this context 
(Mittelstadt and Floridi 2016). The consequence is that one can rely on similar safe-
guards, especially in terms of the procedures, policies and tools that are already 
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applied in the healthcare context, such as de-identification and encryption.14 The 
fact that these data would be donated does not affect these concerns substantially.
The second source of risks concerns the provenance of the donated medical data 
and the potential use to which the donated data can be put. Because the donor is 
deceased, PMDD has a lower (or perhaps no) negative impact on the donor, com-
pared with sharing one’s medical data when alive. However, safeguarding is also 
lower, since individuals may indicate how their data may be used or repurposed 
while they are alive, but of course have no control once dead. It is therefore crucial 
to develop a framework that respects the values and preferences of the data donors, 
and that reassures potential donors that their expressed wishes will be respected 
after death. In particular, concerns over the misuse of medical Big Data to justify 
unfair public policies, the implementation of medical profiling outside of the health 
care context (e.g. by employers or insurance companies), and the application of IP 
rights to lock-in or restrict access to medical insights and advances derived from 
donated medical data have to be taken seriously, and need to be addressed.
For all these reasons, an ethical code of PMDD is needed to these issues effec-
tively. With regard to the first risk (of harm to relatives), encouraging the active 
involvement of family members and relatives prior to a decision to participate in 
PMDD could resolve many of the potential concerns, similar to the existing recom-
mendations in organ or body donation. As it has been argued, a “do not use if in 
doubt” approach is also practicable, as the value of any single data set is limited and 
unlikely to have an impact on the utility of the overall PMDD database. Note that 
this is also an argument against the need to impose a “duty to easy rescue”, and 
hence a suspension of the need to have informed consent: one organ not donated 
may mean a life not saved, but one data set not included makes in itself little differ-
ence to population-based medical studies.
The second risk (lack of control once deceased) can be mitigated by means of a 
value-based framework that firmly places key ethical principles—such as respect 
for persons, human dignity, privacy and integrity, amongst others—at the heart of 
PMDD. Two valuable resources can be drawn on to inform such a code. First, the 
lessons learned from past mistakes made in the context of biomedical data schemes, 
such as the NHS Care.data programme, as well as the best practices of ongoing 
initiatives, such as the Personal Genome Project UK. And second, the ethical and 
governance frameworks currently in place for other types of donations, most cru-
cially those used in biobanking, organ and body donation. An ethical code for 
PMDD must learn from the solutions already found for both these resources, and be 
coherent with them. In the next chapter, we set out to codify some of the lessons and 
best practices that currently exist in an unstructured form to develop a functional 
ethical code for PMDD, as well as leverage the important work done by others in 
developing ethical frameworks for other types of biomedical donations (see Chap. 
12).
14 For example, see the Wellcome Trust’s 2013 “Summary report of qualitative research into public 
attitudes to personal data and linking personal data”, available at: https://wellcomelibrary.org/item/
b20997358#?c=0&m=0&s=0&cv=0
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11.6  How to Implement Ethical PMDD
The first step towards the development of an ethical code for PMDD presented in 
this article was a thorough review of existing ethical frameworks. The focus was in 
particular on tissue, brain, and body donation, as well as the sharing of genomic 
information, because of their similarities with PMDD. However, our analysis also 
revealed some key differences (discussed above), limiting direct comparability with 
our proposed scheme, and reinforcing our belief that a dedicated code is needed for 
PMDD. In this section, some past and current biomedical data projects are considered 
to identify relevant lessons and best practice.
11.6.1  Learning from Mistakes and Codifying Best Practice
Big Data in health care is often described as the biggest opportunity of our times to 
improve public and individual health, and it is therefore no surprise that a vast 
number of data-related projects are ongoing in health care. While there are key 
differences among the initiatives, including in data ownership, access rights and 
purpose, their success—in terms of ethics—can be evaluated on the basis of adherence 
to a number of fundamental principles.
At the unsuccessful end of the spectrum, initiatives like the UK’s disastrous 
Care.data serve as a reminder that neglecting these principles can lead to the com-
plete failure of a well-intended scheme. As the Nuffield Council on Bioethics has 
explained, “Care.data is a salutary lesson in the need for robust and timely public 
engagement – as opposed to mere communication – and in understanding the range 
of ways in which data subjects might perceive harms arising from uses of their 
data.”15 The consequences of this incident can still be felt, and have led to a deep 
distrust in data sharing between the NHS and commercial partners. This is in con-
trast with other countries, where better management of communication and public 
engagement has led to wide public support of similar programmes (Patil et al. 2016).
Unfortunately, it seems that some of the lessons learnt from the Care.data deba-
cle have not yet been applied. The recent introduction of the “GP at hand” video- 
consultation smartphone app, for which NHS England partnered with Babylon 
Health, has met with skepticism both from GPs and the general public. Concerns 
quickly arose over inequality in the treatment of patients, especially those with 
complex health needs, ultimately leading to a suspension of the planned wider roll- 
out of the service (Finlayson et al. 2017). The lack of proper evaluation of the ser-
vice has also been criticised (Rosen 2017), and concerns raised over the privacy 
management, given Babylon Health assumes ownership of the recorded video 
15 See: Laurie et al. (2014) “A review of evidence relating to harm resulting from uses of health and 
biomedical data” available at https://nuffieldbioethics.org/wp-content/uploads/FINAL-Report-on-
Harms-Arising-from-Use-of-Health-and-Biomedical-Data-30-JUNE-2014.pdf
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 consultations in its terms and conditions.16 Although this might seem unlikely to be 
enforced in practice, in theory this means that patients are not allowed to share their 
video consultations with health care professionals who are not enrolled with 
Babylon’s GP at hand service without the company’s prior permission. Considering 
that the service was commissioned by NHS England, most patients are likely to be 
unaware of this restriction, and hiding such an important point in the legal text does 
not exemplify good communication or foster trust between the NHS, its third-party 
partners, and patients.
In the context of genetic data, the Icelandic genetic testing company, deCODE 
Genetics, provides another example of how public trust is all too easily disap-
pointed. In 2012, the company decided to sell out to the American pharmaceutical 
company Amgen—including the DNA and health data of approximately 140,000 
Icelandic individuals held by deCODE. Most of these people had volunteered their 
data on the basis that the company would create a universal health database of 
Icelanders for research purposes, as it had promised in the late 1990s but never 
delivered (Greely 2012).
Sustainability is crucial for any health-related Big Data project, as its success 
will depend on a long-term commitment to research. Unfortunately, this aspect is 
often neglected. A few years ago, the Finnish government (in cooperation with some 
private sector companies) launched the ambitious project of setting up a single plat-
form for the storage of information on the health and well-being of the population. 
The idea was that this could be accessed by health care providers to offer more 
efficient and effective care, and to prevent ill health. The service, taltioni.fi, was 
lauded as sustainable and trustworthy, not least because of its cooperative nature 
and the fact that it involved both the public and private sectors (Riso et al. 2017). 
However, the platform vanished shortly after its launch, and it is not known what 
happened to any data stored within it.17
At the other end of the spectrum are projects like the “Patients Like Me” network, 
which according to its website, is “unleashing the power of data for good (…) by 
empowering people to take control of their health.”18 The company provides a detailed 
and clear privacy policy, including plain language explanations in addition to legal 
texts, and provides users with comprehensive options to manage the sharing of their 
data with third parties, such as private corporations and commercial vendors.
The Personal Genome Project UK (PGP-UK) is equally transparent about data 
access, but goes one step further by providing the de-identified genomic informa-
tion as fully Open Data. Individuals can choose to withdraw their data at any point 
but are made aware, before enrolment, that such a withdrawal cannot necessarily 
prevent all future uses of the data, as copies of it may have been downloaded from 
the website. The PGP-UK is complex in that it involves sharing of genomic data as 
16 See: https://web.archive.org/web/20171114123501/https://www.gpathand.nhs.uk/legal/terms 
(accessed March 5, 2018).
17 As reported by the Finnish Data Protection Office: http://www.tietosuoja.fi/fi/index/
blogi/6IUtCELFH/2017/XHtWkkNPr.html.stx (accessed March 5, 2018).
18 See: https://www.patientslikeme.com/about
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Open Data, and this is reflected in the informed consent procedure, which requires 
participants to pass an enrolment exam before being admitted to the project.
Even a deep commitment to ethical principles offers no guarantee that things will 
never go wrong, as accidental breaches are always possible. In 2014, the PGP suf-
fered a setback when it accidentally disclosed some of the participant email 
addresses and names to other participants.19 Due to a configuration error, replies to 
an email from the PGP-UK were sent to the entire mailing list rather than the 
PGP-UK staff only, thereby revealing the sender’s identity to the members of the 
list. Some 220 people were affected, and the issue was quickly discussed within the 
ethics community, where it was described as a failure both in privacy and trust.20 
This is just one interpretation, as the PGP-UK notified and apologised immediately 
after the event, but the incident indicated that risk from human error is hard to elimi-
nate. As one of the commentators in the discussion noted, the email blunder was a 
suitable way to identify those prospective participants who merely pay lip service to 
the idea of openly sharing their data.
Recently, cooperative models for managing personal health data have gained 
popularity. Switzerland currently has two such schemes, healthbank and 
MIDATA. Both enable citizens to be in control of the storage, management and 
access of their personal health and health-related data, including the decision how 
to share it. Schemes like these find their inspiration in citizen science, whereby 
members of the public can contribute actively to medical research by providing 
access to their personal data. As these platforms are fairly recent developments and 
are not yet in place in most countries, it remains to be seen how they will be adopted 
by the public. However, their cooperative approach certainly carries great potential 
for the future management of personal health data.
11.6.2  Deriving Relevant Ethical Principles
Drawing on the review of the literature and relevant biomedical donation schemes 
and projects, and the input from the participants of two workshops on the ethics of 
data donation,21 the following five ethical principles or categories emerged as most 
relevant to PMDD:
19 See: https://www.personalgenomes.org.uk/archive/email-storm-incident-and-apology (accessed 
March 5, 2018).
20 See, for example, Boddington (2014) “Personal Genome Project UK email disaster: If you can’t 
guarantee privacy, at least try to ensure trust”, available at: http://blog.practicalethics.ox.ac.
uk/2014/05/personal-genome-project-uk-email-disaster-if-you-cant-guarantee-privacy-at-least-
try-to-ensure-trust/ (accessed March 5, 2018).
21 Two workshops on the ethics of medical data donation were held in Oxford in October 2017 and 
April 2018, which included experts from academia, policy-making and industry. In addition to 
common principles from the academic literature, valuable points from practice were shared and 
contributed to the identification of key ethical principles for PMDD. The workshops were sup-
ported by a research grant from Microsoft Research.
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 1. Human dignity and respect for persons
 2. Promotion of the common good
 3. The right to “Citizen Science”
 4. Quality and good data governance
 5. Transparency, accountability, and integrity
These might at first glance appear rather generic and hardly ground-breaking. One 
might also question how these can be applied in practice. In response, we lay out the 
specific requirements for an “Ethical Code for Posthumous Data Donation” in the 
Appendix, which provides more detail on a practical implementation. The Code is 
not a governance framework, so some practical issues will still need to be addressed 
before implementing a PMDD scheme. With regard to the generality of the princi-
ples, this is crucial to preserve sufficient flexibility to account for future develop-
ments. Considering that PMDD is going to be a long-term endeavour, it is important 
to regulate for the future, i.e. to avoid ethical guidelines becoming inapplicable 
due to technological, legal, cultural or social changes. This is the goal of the Code 
proposed here: to provide normative principles shaping PMDD, rather than a set of 
specific rules of conduct for the involved actors. These are not based on any singular 
ethical approach (such as a consequentialist ethics) but build on human rights, the 
concept of human dignity and bioethical principles, including research ethical 
principles.
11.7  Conclusion
In light of both the benefits and potential risks involved in wide donation of personal 
medical data, there is a need for an ethical code of PMDD that addresses key chal-
lenges, including consent, privacy, security and ownership. The previous work done 
in relation to other types of biomedical donation acts as a useful resource to inform 
such a code but cannot simply be extended to PMDD, which comes with its own 
particular ethical challenges.
It is argued that most of these issues have practical solutions, and that the pri-
mary focus should be on managing permissible access and use of the collected data. 
Procedural safeguards have already been developed in other relevant and compara-
ble areas of medical research and could be adopted to foster PMDD. Consider for 
example the broad consent procedures currently used in biobanking or the “educate- 
before- you-sign” approach similar to the one used by the PGP-UK.  This would 
ensure that any individual wishing to donate medical data could make a decision 
that is maximally informed  (Sheehan 2011). Privacy risks could be mitigated by 
managing carefully access to donated data. At the same time, it is important to 
emphasise that no safety measures will ever be fail-safe, and openness about this 
fact should form part of the ethical design of PMDD procedures.
The code developed here (see the following chapter) addresses the key ethical 
issues arising from PMDD. Arguably, before being adopted, further input should be 
J. Krutzinna et al.
179
obtained from a wider audience, for instance through public engagement, to investigate 
public support. However, this is only the first step towards more comprehensive use 
of health-relevant data for the common good. In the future, combining corporate 
data (via data philanthropy) with data sharing and PMDD might open up even 
greater possibilities for supporting health care and research. But for this to work, 
PMDD must first be brought to life.
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